Regeneron, Sanofi: UnitedHealth Selects Praluent Injection For Preferred Access

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and French drug-maker Sanofi (SNYNF, SNY) announced Friday that UnitedHealth Group (UNH) will provide preferred access to Praluent (alirocumab) Injection through OptumRx and UnitedHealthcare for Commercial, Medicare, and Managed Medicaid patients.

Praluent is the only PCSK9 inhibitor preferred across UnitedHealth Group formularies, including OptumRx and UnitedHealthcare Commercial, Medicare, and Managed Medicaid formularies.

The companies noted that Praluent is the only PCSK9 inhibitor currently available in two doses, that allows a healthcare provider to adjust the dose based on their patient's LDL cholesterol lowering needs.

Praluent is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease or ASCVD who require additional lowering of low-density lipoprotein (LDL) cholesterol.

Robert Terifay, Senior Vice President, Commercial, Regeneron, said, "Both the Praluent 75 mg and 150 mg doses will be preferred on UnitedHealth formularies, providing physicians with the flexibility to individualize dosing for their patients."